We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+72.19%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$416M
Cap. Flow
+$154M
Cap. Flow %
13.42%
Top 10 Hldgs %
42.31%
Holding
115
New
23
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.2M
2
APGE icon
Apogee Therapeutics
APGE
+$18.4M
3
ABVX
Abivax
ABVX
+$15.9M
4
SLNO
Soleno Therapeutics
SLNO
+$14.8M
5
CYTK icon
Cytokinetics
CYTK
+$14.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$32M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$12.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$8.84M
4
INZY
Inozyme Pharma
INZY
+$7M
5
VERA icon
Vera Therapeutics
VERA
+$5.59M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTXW
101
DELISTED
Immatics N.V. Warrants
IMTXW
– –
-187,204
Closed -$112
INMB icon
102
PUT
INmune Bio
INMB
$52.9M
– –
-354,000
Closed -$818K
INZY
103
DELISTED
Inozyme Pharma
INZY
– –
-1,749,359
Closed -$7M
MIRM icon
104
Mirum Pharmaceuticals
MIRM
$7.11B
– –
-24,692
Closed -$1.26M
NKTX icon
105
Nkarta
NKTX
$184M
– –
-800,000
Closed -$1.33M
NVAX icon
106
CALL
Novavax
NVAX
$1.3B
– –
-250,000
Closed -$1.57M
QURE icon
107
CALL
uniQure
QURE
$2.73B
– –
-100,000
Closed -$1.39M
THRD
108
DELISTED
Third Harmonic Bio
THRD
– –
-370,000
Closed -$2.01M
RAPP
109
Rapport Therapeutics
RAPP
$1.92B
– –
-199,643
Closed -$2.27M
OKUR
110
OnKure Therapeutics
OKUR
$166M
– –
-347,990
Closed -$832K
RADX
111
Radiopharm Theranostics
RADX
$33.7M
– –
-35,635
Closed -$166K
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Affinity Asset Advisors held 115 positions worth $1.15B, up 57% from $732M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $154M of net new capital in Q3 2025, opening 23 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $12.5M trimmed.

  • Affinity Asset Advisors's largest Q3 2025 buy was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q3 2025, an estimated $18.4M increase.
  • Affinity Asset Advisors's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $12.5M.
  • Affinity Asset Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $32M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.15B portfolio in Q3 2025.
  • Affinity Asset Advisors opened 23 new positions and closed 19 in Q3 2025.
  • Affinity Asset Advisors's portfolio value rose 57% quarter-over-quarter to $1.15B.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.